Full Press Release Details
Ultragenyx Announces FDA Approval of MEPSEVII (vestronidase alfa), the First Therapy for Progressive and Debilitating Rare Genetic Disease Mucopolysaccharidosis VII.
RARE
Ultragenyx Announces FDA Approval of MEPSEVII (vestronidase alfa), the First Therapy for Progressive and Debilitating Rare Genetic Disease Mucopolysaccharidosis VII
Key Takeaway: Ultragenyx Announces FDA Approval of MEPSEVII (vestronidase alfa), the First Therapy for Progressive and Debilitating Rare Genetic Disease Mucopolysaccharidosis VII